Thermogenesis Holdings Inc
F:THR
Thermogenesis Holdings Inc
Goodwill
Thermogenesis Holdings Inc
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Thermogenesis Holdings Inc
F:THR
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Goodwill
$18.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Stryker Corp
NYSE:SYK
|
Goodwill
$19.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Goodwill
$24B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
10%
|
|
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
Goodwill
$413.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Goodwill
$370.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
6%
|
|
Thermogenesis Holdings Inc
Glance View
ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. The company is headquartered in Rancho Cordova, California and currently employs 39 full-time employees. The firm provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for large scale cell manufacturing services. The company manufactures and markets three categories of products, Clinical Bio-Banking Applications, Point-of-Care Applications, and Large Scale Cell Processing and Biomanufacturing. Its Clinical Bio-Banking Applications includes AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Point-of-Care Applications includes PXP Point-of-Care System, PXP-LAVARE System and PXP-1000 System. Its Large Scale Cell Processing and Biomanufacturing includes X-Series Products for general laboratory useand CAR-TXpress Platform for clinical manufacturing.